Pharmacokinetics of vancomycin in anuria

Area of Science:

• Pharmacology
• Nephrology
• Infectious Diseases

Background:

• Vancomycin is a critical antibiotic for treating serious Gram-positive infections.
• Anephric patients (those without kidney function) require careful drug dosing due to altered elimination pathways.

Purpose of the Study:

• To characterize the pharmacokinetics of vancomycin in anephric patients.
• To establish an optimized vancomycin dosing regimen for anephric individuals.

Main Methods:

• Serum vancomycin concentrations were measured in 29 anephric patients after a single 1-g intravenous dose.
• Pharmacokinetic parameters, including elimination half-life and rate constant, were calculated.
• The effect of intermittent dialysis on vancomycin levels was assessed.

Main Results:

• A single 1-g intravenous dose resulted in a mean peak serum concentration of 48.3 micrograms/ml.
• Vancomycin exhibited a biphasic elimination pattern, consistent with a two-compartment model.
• The elimination half-life in anephric patients was significantly prolonged at 7.5 days, compared to 8 hours in normal patients.
• Intermittent dialysis showed no significant impact on serum drug levels.

Conclusions:

• Anephric patients demonstrate significantly prolonged vancomycin elimination, necessitating adjusted dosing strategies.
• A recommended regimen of an initial 1-g dose followed by 500 mg every eight days maintains therapeutic vancomycin concentrations while minimizing toxicity risk.
• This regimen provides peak levels below toxic thresholds and trough levels above minimal inhibitory concentrations for common shunt pathogens.